LGL Group (NYSEAMERICAN:LGL) Stock Passes Above 200 Day Moving Average – Here’s Why

LGL Group, Inc. (The) (NYSEAMERICAN:LGL)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.45 and traded as high as $7.15. LGL Group shares last traded at $7.05, with a volume of 9,613 shares changing hands.

LGL Group Stock Down 3.5%

The company has a market cap of $38.60 million, a P/E ratio of 41.06 and a beta of 0.31. The business has a fifty day simple moving average of $7.02 and a two-hundred day simple moving average of $6.46.

Insider Transactions at LGL Group

In other LGL Group news, major shareholder Mario J. Gabelli bought 95,387 shares of LGL Group stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $4.75 per share, with a total value of $453,088.25. Following the completion of the acquisition, the insider owned 572,324 shares in the company, valued at approximately $2,718,539. This represents a 20.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC acquired a new stake in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group at the end of the most recent reporting period. Institutional investors own 30.28% of the company’s stock.

LGL Group Company Profile

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.